Találati lista | Tudóstér

001-es BibID:	BIBFORM013921
Első szerző:	Soltész Pál (belgyógyász, kardiológus)
Cím:	Comparative assessment of vascular function in autoimmune rheumatic diseases : consideration of prevention and treatment / Soltész Pál, Kerekes György, Dér Henrietta, Szűcs Gabriella, Szántó Sándor, Kiss Emese, Bodolay Edit, Zeher Margit, Tímár Orsolya, Szodoray Péter, Szegedi Gyula, Szekanecz Zoltán
Dátum:	2011
ISSN:	1568-9972
Megjegyzések:	Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis or other types of vasculopathy leading to increased cardio- and cerebrovascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. The characteristics of vasculopathies may significantly differ depending on the underlying disease. While classical accelerated atherosclerosis has been associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or spondyloarthropathies (SpA), obliterative vasculopathy may rather be characteristic for systemic sclerosis (SSc) or mixed connective tissue disease (MCTD). Antiphospholipid antibodies have been implicated in vasculopathies underlying SLE, antiphospholipid syndrome (APS), RA and MCTD. There is also heterogeneity with respect to inflammatory risk factors. Cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interleukin 6 (IL-6) and immune complexes are primarily involved in arthritides, such as RA, SpA, as well as in SLE. On the other hand, autoantibodies including anti-oxLDL anti-cardiolipin and anti-beta2GPI are rather involved in SLE- and APS-associated vasculopathies. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have just been published, and similar recommendations in connective tissue diseases are to be developed soon.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Autoimmunity Reviews. - 10 : 7 (2011), p. 416-425. -
További szerzők:	Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Dér Henrietta (1977-) (orvos) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Tímár Orsolya (1980-) (belgyógyász) Szodoray Péter (1973-) (belgyógyász, orvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI elektronikus változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM007083
Első szerző:	Soltész Pál (belgyógyász, kardiológus)
Cím:	Cardiac manifestations in antiphospholipid syndrome / Soltesz, P., Szekanecz, Z., Kiss, E., Shoenfeld, Y.
Dátum:	2007
ISSN:	1568-9972 (Print)
Megjegyzések:	Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Antibodies Antiphospholipid Antiphospholipid Syndrome Atherosclerosis Autoantibodies Cardiovascular Diseases Humans Risk Factors Thrombosis
Megjelenés:	Autoimmunity Reviews. - 6 : 6 (2007), p. 379-386. -
További szerzők:	Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:	elektronikus változat elektronikus változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM040289
Első szerző:	Szekanecz Éva (onkológus szakorvos)
Cím:	Malignancies and soluble tumor antigens in rheumatic diseases / Szekanecz E., András C., Sándor Z., Antal-Szalmás P., Szántó J., Tamási L., Kiss E., Szekanecz Z.
Dátum:	2006
ISSN:	1568-9972
Megjegyzések:	Paraneoplastic symptoms, caused by a malignancy, but not directly related to invasion by the tumor or its metastases are the result of a wide variety of tumor-derived biologic mediators like hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. There is some evidence that systemic inflammatory diseases, such as rheumatoid arthritis (RA), lupus, scleroderma or dermatomyositis may increase the risk for the development of malignancies, predominantly lymphoproliferative disorders. However, reports are somewhat controversial. Immunosuppressive and cytotoxic drugs used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anti-TNF biologicals may also lead to the development of such tumors. Tumor-associated antigens may be produced by inflammatory cells and their production may be increased in RA and other autoimmune diseases.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 6 : 1 (2006), p. 42-47. -
További szerzők:	András Csilla (1961-) (onkológus szakorvos) Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szántó János (1949-) (onkológus szakorvos) Tamási László Kiss Emese (1960-) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: